Actively Recruiting
Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms
Led by Memorial Sloan Kettering Cancer Center · Updated on 2025-10-09
25
Participants Needed
8
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is for researchers to find ways of detecting pancreatic ductal adenocarcinoma/PDAC early to avoid the invasive procedure of surgery. The study researchers think a combination of imaging and a series of blood tests may be an effective way to detect PDAC early. In this study, researchers will look at whether a combination of the following types of imaging with blood tests can detect PDAC in pancreatic cysts: * The ImmunoPET scan (immune-positron emission tomography scan) with the imaging agent 89Zr-DFO-HuMab-5B1 * The HP MRI scan (hyperpolarized pyruvate magnetic resonance imaging scan)
CONDITIONS
Official Title
Hyperpolarized C Pyruvate Magnetic Resonance Imaging, and Blood-Based Biomarkers for Early Detection of Pancreatic Adenocarcinoma in Patients With Intraductal Papillary Mucinous Neoplasms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women aged >18 years
- Pancreatic cystic neoplasm deemed to be high risk and requiring surgical resection
- Able to provide informed consent
You will not qualify if you...
- Pathologic evidence of pancreatic cancer
- Pregnant or breast-feeding patients
- Refusal or inability to tolerate scan (eg anxiety or claustrophobia)
- Inability to lay flat or meet the standard requirements of traditional MRI
- Hepatic function abnormalities within 6 weeks prior to enrollment: Bilirubin > 1.5 x ULN, AST/ALT > 2.5 x ULN, Albumin < 3 g/dL, GGT > 2.5 x ULN if Alkaline Phosphatase > 2.5 x ULN
- Renal function abnormalities within 6 weeks prior to enrollment: Creatinine > 1.5 x ULN or creatinine clearance < 60 mL/min
- Cardiac conditions including congestive heart failure with NYHA status ≥2, poorly controlled hypertension, significant EKG abnormalities, or myocardial infarction within 6 months of enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, United States, 07920
Actively Recruiting
2
Memorial Sloan Kettering Monmouth (Limited protocol activities)
Middletown, New Jersey, United States, 07748
Actively Recruiting
3
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, United States, 07645
Actively Recruiting
4
Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity)
Commack, New York, United States, 11725
Actively Recruiting
5
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, United States, 10604
Actively Recruiting
6
Memorial Sloan Kettering Cancer Center (All protocol activites)
New York, New York, United States, 10065
Actively Recruiting
7
Weill Cornell Medical Center (Specimen Analysis Only)
New York, New York, United States, 10065
Not Yet Recruiting
8
Memorial Sloan Kettering Nassau (Limited Protocol Activites)
Rockville Centre, New York, United States, 11553
Actively Recruiting
Research Team
K
Kevin Soares, MD
CONTACT
D
David Kelson, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here